1. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson’s disease;Addy;J. Clin. Pharmacol.,2009
2. Trial watch: phase II failures: 2008–2010;Arrowsmith;Nat. Rev. Drug Discov.,2011
3. Trial watch: phase II and phase III attrition rates 2011–2012;Arrowsmith;Nat. Rev. Drug Discov.,2013
4. The promise and peril of chemical probes;Arrowsmith;Nat. Chem. Biol.,2015
5. Baptista, M.A., Merchant, K.M., Bharghava, S., Bryce, D., Ellis, M., Estrada, A.A., Fell, M., Fuji, R.N., Galatsis, Hill, S., et al. (2015). LRRK2 Kinase Inhibitors of Different Structural Classes Induce Abnormal, but Reversible, Accumulation of Lamellar Bodies in Type II Pneumocytes in Non-human Primates but are Reversible and without Pulmonary Functional Consequences. https://www.michaeljfox.org/files/foundation/LSIposter_SfN2015.pdf.